Among them, retatrutide has shown significant clinical advantages in phase II clinical trials, reducing the weight of obese patients by up to 24.2% in 48 weeks and lowering the HbA1c of type 2 diabetes patients by 2.2% in 36 weeks (49, 50)
Evaporative dry eye disease due to meibomian gland dysfunction: preferred practice pattern guidelines for diagnosis and treatment
Think frozen berries for smoothies or frozen mixed veggies for stir-fries
Septic-associated encephalopathy: A comprehensive review
With one or two sessions per year, many patients report lasting improvements without the need for constant re-administration
The estimated annual cost of obesity in Canadaincluding hospitalizations, medications, long-term care, and premature mortalityis approximately $27 billion per year